![]() Price-to-Profit (also referred to as price to earnings, P/E ratio) is 59 which means that the stock price compared with what market professionals expect for future profits is lower than for 59% of comparable companies, indicating a good value concerning Quest Diagnostics's profit levels. The Value Rank is based on consolidating four value indicators, with three out of four indicators above average for Quest Diagnostics. Stock analysis on combined financial performance: The higher the rank of Quest Diagnostics the better the performance.ĪNALYSIS: With an Obermatt Value Rank of 76 (better than 76% compared with alternatives) for 2023, Quest Diagnostics shares are significantly less expensive than comparable stocks. Last update of combined financial performance. Upgrade to a Premium Account to access the latest ranks. The higher the rank, the better Quest Diagnostics is in the corresponding investment strategy. Stock research history is based on the Obermatt Method. Financial reporting date used for calculating ranks: 3. Most recent update of the stock research. Log in or sign up to see the new 360° View and Sentiment ranks. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. If you believe that low growth is temporary or just due to a specific current event, you may conclude that the good value of the stock provides an attractive investment opportunity. The good value, better than 76% of comparable companies, may indicate the company's future is challenging. RECOMMENDATION: A Combined Rank of 34, is a hold recommendation based on Quest Diagnostics's financial characteristics.Īs the company Quest Diagnostics's key financial metrics exhibit good value (Obermatt Value Rank of 76) but low growth (Obermatt Growth Rank of 11) and risky financing practices (Obermatt Safety Rank of 42), it may be a risky investment, because debt in times of crises can make things worse. Shares of Quest Diagnostics are a good value (attractively priced) with a consolidated Value Rank of 76 (better than 76% of alternatives) but show below-average growth (Growth Rank of 11), and are riskily financed (Safety Rank of 42), which means above-average debt burdens. Quest Diagnostics stock research in summaryĪNALYSIS: With an Obermatt Combined Rank of 34 (worse than 66% compared with investment alternatives), Quest Diagnostics (Health Care Services, USA) shares have somewhat below-average financial characteristics compared with similar stocks.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |